Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2342 | Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
In December 2019, a new viral disease called COVID-19 emerged. It is caused by the new corona virus SARS-CoV-2. It was initially described in the chinese city of Wuhan. In the following months, the disease developed into a pandemic, which is currently an immense international challenge. So far, there is little scientific evidence on risk stratification, especially on the prognostic value of biomarkers (laboratory-chemical, clinical and digital) with regard to clinical deterioration of patients with COVID-19. Further scientific studies are needed to establish optimal risk stratification and early detection of clinical deterioration. In this study, the investigators aim to observe patients with COVID-19 via SmartWatches on top of their clinical routine. The investigators aim to determine, whether the addition of SmartWatches enhances risk stratification, early detection of complications and prognostics in patients with COVID-19, who have cardiovascular diseases or receive medication with arrhythmogenic risk.
Description: Identification of biomarkers (laboratory-chemical, clinical, digital) for risk stratification, early detection of complications and prognosis
Measure: Biomarker Time: 3 monthsDescription: Identification of laboratory-chemical, clinical or digitally measured protective factors, that indicate good prognosis
Measure: Protective factors Time: 3 monthsDescription: The amount of time is compared between participants regarding the wearing of a SmartWatch as a monitoring tool
Measure: SmartWatch compliance Time: 3 monthsDescription: Detection of an irregular heartbeat (PPG) as a sign of atrial or ventricular arrhythmias and correlation to intermittently recorded ECGs by SmartWatch
Measure: Arrhythmias Time: 3 monthsDescription: Detection of QT time changes (prolongation) in intermittently recorded ECGs by SmartWatch and correlation with clinical variables (change of medication, fever, etc.)
Measure: QT time changes Time: 3 monthsDescription: Application of artificial intelligence and machine learning techniques for longitudinal risk models by using collected data (e.g. metabolomics)
Measure: Longitudinal risk models Time: 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports